Abstract
INTRODUCTION: Our recent studies revealed that embryonic stem cells are superior to adult bone marrow mesenchymal stem cells (aBMSC) in protecting native tissue following ischemia. It seemed logical that BMSCs from younger hosts (neonates nBMSC) may be more potent and functionally distinct when compared to aBMSC. But nBMSCs have not yet been explored. We hypothesized that nBMSCs: 1) represent a phenotypically distinct stem cell source; 2) produce more IGF-1 than aBMSC following stimulation; and, 3) exhibit greater stimulated MAPKactivation than aBMSCs.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
